Gerardo Cárdenas Vogel, CEO of Innovare R&D, on transforming the company’s business model to benefit from drug development opportunities, Mexico as a world-class clinical trial destination, and new, innovative treatments as part of their partnership with the French biotech company LFB.
When our colleagues met with you in February 2015, we were impressed to see how Innovare R&D distinguishes itself from most Mexican players: a research and innovation driven company, focused on intangible assets and on attracting clinical research investments in Mexico. To what extent has this unique positioning among the Mexican pharma landscape been paying off?
The increasing interest of the international community in investing in Mexican R&D activities nurtured our desire to transform Innovare’s business model
